D&B Business Directory
BioNumerik Pharmaceuticals, Inc.
Overview
BioNumerik Pharmaceuticals does biopharmaceutical drug development by the numbers. Using a multi-discipline process of identifying potential cancer drugs, the company has brought two candidates into late-stage development. Lead candidate Tavocept, which has FDA fast-track status, may prevent nerve and kidney damage caused by cancer therapies. BioNumerik's Karenitecin candidate is an advanced formulation of an existing cancer drug and is being ...
Read More
evaluated for treatment of solid tumors. The firm relies heavily on computer models and simulations to identify promising drug candidates. In addition to its two lead candidates, it has several other potential drugs in pre-clinical research.
Read Less
Frederick H Hausheer   See more contacts
?
?
Actual

?
Actual
#
Modelled
? ?
Contacts
Get in Touch with 3 Principals* and 1 Contacts
  • Frederick H Hausheer
    Chief Executive Officer and Chairman of the Board
  • Contact 2
    ?
  • Contact 3
    ?
  • Contact 4
    ?
D&B Hoovers Logo

Dynamic search and list-building capabilities

Real-time trigger alerts

Comprehensive company profiles

Valuable research and technology reports

Financial Data
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Stay on top of your Business Credit File
Get full access to view your D&B business credit file now for just $39/month!
View D&B Scores & Ratings